CME online

in association with the 7th Heart in Diabetes (HiD)

New Frontier in Diabetes Kidney and Heart Disease

This is a CME Symposium Supported by an Educational Grant from Bayer
Provided By:

Administrated by:
This CME online educational activity is approved for a maximum of 1.5 AMA PRA Category 1 Credits ™.
Accreditation period: August 1, 2023 – August 1, 2024

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

New Frontier in Diabetes Kidney and Heart Disease
Agenda

Introduction & Pre-CME Questions
George L. Bakris, MD

From Kidney to Heart Disease- Albuminuria, Inflammation, and Fibrosis
Robert Toto, MD

Finerenone Effects on Metabolism, Morbidities, and Mortality in CKD and T2D
Mikhail N. Kosiborod, MD

The Changing Trajectory of DKD
George L. Bakris, MD

Panel Discussion, Q&A, and Post-CME: Impact of Pathophysiology-Based Treatment on Outcome
Panel: : George L. Bakris, MD • Vivian A. Fonseca, MD • Mikhail N.Kosiborod, MD • Robert Toto, MD
Moderator: Yehuda Handelsman, MD

Faculty

George L. Bakris, MD

Professor of Medicine Director,
AHA Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Yehuda Handelsman, MD, FACC, FAHA, FACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory board, DCMi– Diabetes
CardioRenal & Metabolism Institute
Chair & Program Director, Heart in Diabetes
Tarzana, California

Mikhail N. Kosiborod MD FACC, FAHA

Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City
School of Medicine
Chair, Heart in Diabetes
Kansas City, Missouri

Robert Toto, MD

Professor of Medicine Associate
Dean Translational Science and Education
Distinguished Teaching Professor Director,
Center for Translational Medicine
Principal Investigator,
UT Southwestern CTSA Program
Dallas, Texas

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni
Chair in Diabetes Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Program Description

Diabetic kidney disease (DKD) and type 2 diabetes (T2D) share a common etiology involving hyperglycemia, hypertension, inflammation, oxidative stress, fibrosis, mineralocorticoid receptor activation and increased renin-angiotensin-aldosterone system (RAAS) activity, and all of these pathophysiologic factors contribute to the development of chronic kidney disease (CKD). Both CKD and T2D are common, and together more than doubles the risk of CVD and triples the risk of heart failure.
This satellite symposium will address the pathophysiology of, and screening for- DKD. It will explore the complex challenges of treating these patients and review the contemporary approach to their management highlighting the role of the less known finerenone a non steroidal MRA in reducing progression to ESKD, HF CVD and mortality. The program will examine the changing trajectory of diabetic kidney disease and discussing the Impact of Pathophysiology Based Treatment on Outcome.


Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Describe the etiologic and pathophysiologic links between CKD, T2D, HF, and CVD and the disease burden of CKD and associated cardiometabolic conditions.
  • Discuss the current standards and timing of screaming and diagnosing CKD in DM
  • Compare and contrast the benefits and limitations of treatments indicated for CKD management, including RAAS blockade agents, first generation MRAs, and SGLT2 inhibitors
  • Discuss the evidence for the efficacy, safety, and clinical outcomes of finerenone based on the results of FIDELIO and FIGARO and their role in optimizing cardiorenal outcomes in the management of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D)
  • Design optimal pillars based therapeutic regimens for the prevention and management of CKD progression in diabetes to reduce comorbidities and mortality

    • Target Audience

    This educational initiative is designed for cardiologists, nephrologists, endocrinologists, primary care physicians, internists, and other healthcare professionals interested in the Epidemiology, pathophysiology, prevention, and treatment of diabetes with CKD and prevention of related morbidity and mortality.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc., is accredited by the ACCME to provide continuing medical education for physicians.

    PESI, Inc, designated this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s).

    For information please contact: [email protected] or 818 342 1889

    This is a CME Program Supported by an Educational Grant from Bayer